Recombinant protein · Protein replacement: glucosylceramidase (beta-glucocerebrosidase) (GBA1) · developed by Genzyme
Imiglucerase is a recombinant lysosomal glucocerebrosidase enzyme. It catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, and its mannose sugars mediate uptake by cells such as macrophages. It is used in Gaucher disease, a deficiency of this enzyme that causes glucocerebroside accumulation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 27, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07927140 | Phase 3 | Gaucher's Disease Type III | Not yet recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gaucher's Disease Type III
Updated Nov 15, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →